Us Fda Approves Taigens Ind For Tg-1000 To Treat Influenza A And B

Taigen Biotechnology Company, Limited (Taigen), A Leading Research-Based And Market-Driven Biotechnology Company, Announced That Us Food And Drug Administration (Fda) Has Approved The Investigation New Drug (Ind) Application For Tg-1000, A Novel Treatment For Influenza A And B.Tg-1000 Is A Novel Pan-Influenza Antiviral, Which Interrupts Viral Replication And Transmission Via A Cap-Snatching Mechanism And Is Able To Do This Effectively Against Influenza-A, Influenza-B, Avian Flu H7N9, And Tamiflu-Resistant Viruses. The First Us Patent For Tg-1000 Was Successfully Prosecuted And Granted By The United States Patent And Trademark Office On Jan 14Th, 2020.Kuo-Lung Huang, The Chairman And Ceo Of Taigen Notes, &Ldquo;Influenza Is A Life Threatening Disease With Significant Unmet Medical Needs And High Medical Burden. With The Ind Approval In Place, We Are Ready And Eager To Extend The Clinical Study Of Tg-1000 To The Us In The Near Future.&Rdquo;According To Global Data, The Global Market For Influenza Antivirals Reached Us$ 2.34 Billion In 2019 And Is Estimated To Reach Us$ 5.03 Billion By 2026 At A Cagr Of 11.5%. Currently The Market Is Comprised Primarily Of The Neuraminidase Inhibitor Oseltamivir And The Newly Developed Endonuclease Inhibitor Baloxavir. With The Recent Introduction Of Baloxavir Into The Market, Institutional Investment Analysts Expect The Market Share Of Endonuclease Inhibitors To Increase At The Expense Of Neuraminidase Inhibitors. Taigen&Rsquo;S Tg-1000 Is Poised To Take Full Advantage Of This Development.Taigen Biotechnology Is A Leading Research-Based And Market-Driven Biotechnology Company In Taiwan With A Wholly-Owned Subsidiary In Beijing, China.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!